

common compared with tricyclic antidepressants. Venlafaxine treatment stimulated expression of brain derived neurotrophic factor protein in the frontal cortex and inhibited long-term potentiation in the hippocampus (33). In another study, the relationship between the antidepressant effect of venlafaxine and its ability to protect animals against stress-induced oxidative lipid peroxidation and DNA damage was investigated. It was reported that long-term venlafaxine treatment using effective antidepressant doses can protect against stress-

- [5] Corpinella M C., Miranda M., Almiron W R., Ferrayoil C G and palacios S M. In vitro pedicucidal and ovicidal activity of an extract and oil from fruit of *Melia azedarach*. *J Am Acad Dermatol*. 2007, 250-6.
- [6] Wandscheer C B., Duque J E and Da sliva M A. Larvacidal action of ethanolic extracts from fruits endocarps of *Melia azedarach* and *Azedirachta indica* against the dengue mosquito *Aedes Ae gypiti*. *Toxicol*. 2004, 829-35.



- [3] Grower S., Dutt A and Aswathi A. An over view of Insulin Research in depression. *Indian J psychiatry*. 2000, 52: 178-188.
- [4] Han J., Lin W., Xu R S., Wang W L and Zhao S H. Studies on the chemical constituents of *Melia azedarach*. *Acta Pharm.Sin.* (In china), 1991, 426-429.

M, Deger O Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. *J Affect Disord*. 2001, 64:43-51.

- [20] Eren I, Nazroglu M, Demirdas A, Celik O, Uguz AC, Altunbasak A, Ozmen Uz E. Venlafaxine modulates depression-induced oxidative stress in brain and medulla of rat. *Neurochem Res*. 2007, 32:497-505.

- [21] Fontella FU, Siqueira IR, Vasconcellos APS, Tabajara AS, Netto CA, Dalmaz C. Repeated restraint stress induces oxidative damage in rat hippocampus. *Neurochem Res.* 2005, 30:105–111.
- [22] Pal SN, Dandiya PC. Glutathione as a cerebral substrate in depressive behavior. *Pharmacology, Biochemistry, and Behavior* 1994 48, 845–851.
- [23] Khawaja X, Xu J, Liang JJ, Barrett JE. Proteomic analysis of protein changes developing in rat hippocampus after chronic antidepressant treatment: Implications for depressive disorders and future therapies. *Journal of Neuroscience Research* .2004, 75, 451–460.
- [24] Verleye M, Steinschneider R, Bernard FX, Gillardin JM. Moclobemide attenuates anoxia and glutamate-induced neuronal damage in vitro independently of interaction with glutamate receptor subtypes. *Brain Research*. 2007, 1138, 30–38.
- [25] Lee CS, Han ES, Lee WB. Antioxidant effect of phenelzine on MPP⁺-induced cell viability loss in differentiated PC12 cells. *Neurochemical Research*. 2003, 28, 1833–1841.
- [26] Looney JM, Childs HM. The lactic acid and glutathione content of the blood of schizophrenic patients. *Journal of Clinical Investigation*. 1934, 13, 963–968.
- [27] Ben Othmen L, Mechri A, Fendri C, Bost M, Chazot G, Gaha L, Kerkeni A. Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings. *Progress in Neuropsychopharmacology and Biological Psychiatry*. doi:10.1016/j.pnpbp.2007.08.003.
- [28] Srivastava N, Barthwal MK, Dalal PK, Agarwal AK, Nag D, Srimal RC, Seth PK, Dikshit M. Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. *Psychopharmacology* . 2001, 158, 140–145.
- [29] Akyol O, Herken H, Uz E, Fadillioglu E, Unal S, Sogut S, Ozyurt H, Savas HA. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/ antioxidant imbalance. *Progress in Neuropsychopharmacology and Biological Psychiatry*. 2002, 26, 995–1005.
- [30] Buckman TD, Kling AS, Eiduson S, Sutphin MS, Steinberg A. Glutathione peroxidase and CT scan abnormalities in schizophrenia. *Biological Psychiatry*. 1987, 22, 1349–1356.
- [31] Bauer, M; Tharmanathan, P; Volz, H.P; Moeller, H.J. & Freemantle, N.. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. *Eur Arch Psychiatry Clin Neurosci*. 2009, 259(3):172-85.
- [32] Susman, N. SNRIs versus SSRIs: Mechanisms of Action in Treating Depression and Painful Physical Symptoms. *Primary Care Companion J Clin Psychiatry*. 2003;5 [suppl 7]:19–26.
- [33] Cooke, J.D.; Grover, L.M. & Spangler, P.R. Venlafaxine treatment stimulates expression of brain-derived neurotrophic factor protein in frontal cortex and inhibits long-term potentiation in hippocampus. *Neuroscience*. 2009, 15; 162(4):1411-9.
- [34] Abdel-Wahab, B.A.; Salama, R.H. Venlafaxine protects against stress-induced oxidative DNA damage in hippocampus during antidepressant testing in mice. *Pharmacol Biochem Behav*. 2011, 100(1):59-65